CGTX (Cognition Therapeutics) Institutional Ownership: 27.64% (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGTX Cognition Therapeutics Inc CGTX
34 GF Score
Price $0.92
! 1 Warning Sign
View Full Analysis

What is Cognition Therapeutics Institutional Ownership?

Cognition Therapeutics CGTX -4.24% 34 Institutional Ownership is 27.64% as of Jul. 25, 2026. GuruFocus rates CGTX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cognition Therapeutics's institutional ownership is 27.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cognition Therapeutics's Insider Ownership is 4.05%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cognition Therapeutics's Float Percentage Of Total Shares Outstanding is 92.25%.

Cognition Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cognition Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognition Therapeutics Institutional Ownership Chart

Cognition Therapeutics Historical Data

The historical data trend for Cognition Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.67 6.32 6.30 4.49 4.69 4.75 4.76 4.75 4.89 5.47
CGTX
34GF Score
Cognition Therapeutics Inc CGTX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cognition Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 27.64% mean?
Cognition Therapeutics (CGTX) has a Institutional Ownership of 27.64% as of Jul. 25, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cognition Therapeutics and its competitors.
Is Cognition Therapeutics' Institutional Ownership too high?
Cognition Therapeutics' current Institutional Ownership is 27.64%. Overall, Cognition Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cognition Therapeutics' Institutional Ownership compare to PTHS and BDTX?
Cognition Therapeutics' Institutional Ownership of 27.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cognition Therapeutics and its competitors. Cognition Therapeutics's current Institutional Ownership is 27.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognition Therapeutics stock overvalued right now?
Cognition Therapeutics (CGTX) has a current Institutional Ownership of 27.64%. The current Institutional Ownership is 27.64%. Cognition Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cognition Therapeutics (CGTX), the current Institutional Ownership is 27.64% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cognition Therapeutics Business Description

Address 2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
34GF Score

Get the complete analysis for CGTX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price